Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Cells|April 23, 2020
Establishment of an in Vitro Human Blood-Brain Barrier Model Derived from Induced Pluripotent Stem Cells and Comparison to a Porcine Cell-Based SystemAnnalise Di Marco, Domenico Vignone, Odalys Gonzalez Paz, et al.
Molecular Pharmaceutics|March 28, 2019
Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's DiseaseAnnalise Di Marco, Odalys Gonzalez Paz, Ivan Fini, et al.
Journal of Medicinal Chemistry|June 26, 2007
Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic propertiesHui-Ling Wang, Jodie Katon, Chenera Balan, et al.
Plos One|February 8, 2014
A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's diseaseDaniel Todd, Ian Gowers, Simon J Dowler, et al.
Bioorganic & Medicinal Chemistry|October 16, 2020
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interactionStefania Colarusso, Daniele De Simone, Tommaso Frattarelli, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's DiseaseJohn Wityak, Michael E Prime, Frederick A Brookfield, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
N-Aryl-gamma-lactams as integrin alphavbeta3 antagonistsNing Xi, Stephen Arvedson, Shawn Eisenberg, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) InhibitorsChristopher A Luckhurst, Perla Breccia, Andrew J Stott, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2018
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitorChristopher A Luckhurst, Omar Aziz, Vahri Beaumont, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseMichael E Prime, Frederick A Brookfield, Stephen M Courtney, et al.
Pageof 9